CONFIDENTIALITY 3. DŮVĚRNOST
CONFIDENTIALITY 3. .1. The fact that the Agreement has been executed as well as its contents and any technical and financial or other information pursuant to the GARIMPO constitutes confidential information of the CONTRACTING PARTIES and shall not be disclosed, divulged or made known to any third party or published without previous written consent of the non-disclosing party. Exception to the confidentiality obligation will be the case in which any of the CONTRACTING PARTIES needs to disclose said information as a result of it is being linked to the stock market and disclosure is required by law.
CONFIDENTIALITY 3. 1 During the term of this Agreement, OASIS may find it desirable to share its confidential and proprietary business and technical information, e.g., royalty payments and reports, sales volumes, forecasts, business plans, vendors, customers, manufacturing information, test results, product development plans, etc. (CONFIDENTIAL INFORMATION) with TRANSEND. OASIS desires to protect the confidential and proprietary nature of such information as set forth herein.
CONFIDENTIALITY 3. 1Definition “Confidential Information” means the confidential and proprietary information of Sponsor and includes (i) all information disclosed by or on behalf of Sponsor to Institution, Investigator or other Institution personnel, including without limitation, the Investigational Product, technical information relating to the Investigational Product, all Pre- Existing Intellectual Property (as defined in Section 4) of Sponsor, and the Protocol; and (ii) Study enrollment information, information pertaining to the status of the Study, communications to and from regulatory authorities, information relating to the regulatory status of the Investigational Product, and Study Data and Inventions (as defined in Section 4). Confidential Information shall not include information that: (i) can be shown by documentation to have been public knowledge prior to or after disclosure by Sponsor, other than through wrongful acts or omissions attributable to Investigator, Institution or any of its personnel; (ii) can be shown by documentation to have been in the possession of Investigator, Institution or any of its personnel prior to disclosure by Sponsor, from sources other than Sponsor that did not have an obligation of confidentiality to Sponsor; V souvislosti s řádným plněním Studie Zdravotnickým zařízením, a to v souladu s podmínkami a ustanoveními této Smlouvy, budou poskytovány platby dle podmínek a ustanovení definovaných v Příloze A, přičemž poslední platba bude uskutečněna poté, co Místo provádění klinického hodnocení splní a dokončí veškeré závazky, jež mu vyplývají z této Smlouvy, a IQVIA obdrží veškeré řádně vyplněné CRF a, bude-li tak IQVIA vyžadovat, veškeré další Důvěrné informace (ve smyslu níže uvedené definice). Odhadovaná hodnota finančního plnění na základě této Smlouvy bude přibližně 942 157,00 Kč.
CONFIDENTIALITY 3. DŮVĚRNOST a) “Confidential Information” means all confidential or proprietary information or data, of any kind whatsoever and however memorialized, that is: (i) disclosed by or on behalf of the Sponsor to the Institution, the Investigator or the Study Personnel in connection with this Agreement; or (ii) obtained, developed or generated by the Institution, the Investigator and/or the Study Personnel as a result of performing the Study. The Confidential Information shall include, without limitation, the Study, the Study Drug, the Protocol, the Investigator’s Brochure, the Study Data, the Intellectual Property (defined below) and information regarding the Sponsor, its affiliates. All Confidential Information shall belong solely and exclusively to the Sponsor.
CONFIDENTIALITY 3. DŮVĚRNÝ REŽIM
3.1 Definition 3.1
CONFIDENTIALITY 3
